MILWAUKEE, Aug. 23, 2024 /PRNewswire/ — Ademi LLP is investigating Titan (NASDAQ: TTNP) for possible breaches of fiduciary duty and other violations of law in its transaction with KE Sdn. Bhd.
Click here to learn how to join our investigation https://www.ademilaw.com/case/titan-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Titan will engage in a reverse merger with KE and will become minority stockholders of the combined company. Dato’ Seow Gim Shen, Chairman of the Board and Chief Executive Officer of Titan, is the holder of 47.4% of the outstanding shares of KE and non-insider Titan stockholders will own only 13% of the combined companies, post-merger. The transaction agreement unreasonably limits competing transactions for Titan by imposing a significant penalty if Titan accepts a competing bid. Titan insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Titan’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Titan common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/titan-pharmaceuticals-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
